Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

Halozyme is a high beta biotech that moves in accordance with XBI (biotech ETF). As a speculative stock, it moves down higher % than XBI does (as is the case with most small speculative biotechs.) The recent decline is due to nothing but that and the news from ABBVIE.

There is no indication of a problem with the control group. In fact most oncologists involved in the trial are more excited about PEGPH20 than ever before and more so than any other ongoing pancreatic cancer trial. The market will understand this sooner or later and price will go up every day that data is not mature.